Copyright Reports & Markets. All rights reserved.

Global Drugs for Herpes Labialis (Oral Herpes) Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Drugs for Herpes Labialis (Oral Herpes) Market Overview

      • 1.1 Product Overview and Scope of Drugs for Herpes Labialis (Oral Herpes)
      • 1.2 Drugs for Herpes Labialis (Oral Herpes) Segment by Type
        • 1.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 Aciclovir
        • 1.2.3 Valacyclovir
        • 1.2.4 Famciclovir
        • 1.2.5 Docosanol
        • 1.2.6 Other
      • 1.3 Drugs for Herpes Labialis (Oral Herpes) Segment by Application
        • 1.3.1 Drugs for Herpes Labialis (Oral Herpes) Consumption Comparison by Application (2014-2025)
        • 1.3.2 External Use
        • 1.3.3 Oral
        • 1.3.4 Injection
      • 1.3 Global Drugs for Herpes Labialis (Oral Herpes) Market by Region
        • 1.3.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Region
        • 1.3.2 North America Status and Prospect (2014-2025)
        • 1.3.3 Europe Status and Prospect (2014-2025)
        • 1.3.4 China Status and Prospect (2014-2025)
        • 1.3.5 Japan Status and Prospect (2014-2025)
        • 1.3.6 Southeast Asia Status and Prospect (2014-2025)
        • 1.3.7 India Status and Prospect (2014-2025)
      • 1.4 Global Drugs for Herpes Labialis (Oral Herpes) Market Size
        • 1.4.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue (2014-2025)
        • 1.4.2 Global Drugs for Herpes Labialis (Oral Herpes) Production (2014-2025)

      2 Global Drugs for Herpes Labialis (Oral Herpes) Market Competition by Manufacturers

      • 2.1 Global Drugs for Herpes Labialis (Oral Herpes) Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Drugs for Herpes Labialis (Oral Herpes) Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Drugs for Herpes Labialis (Oral Herpes) Production Sites, Area Served, Product Types
      • 2.5 Drugs for Herpes Labialis (Oral Herpes) Market Competitive Situation and Trends
        • 2.5.1 Drugs for Herpes Labialis (Oral Herpes) Market Concentration Rate
        • 2.5.2 Drugs for Herpes Labialis (Oral Herpes) Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Drugs for Herpes Labialis (Oral Herpes) Production Market Share by Regions

      • 3.1 Global Drugs for Herpes Labialis (Oral Herpes) Production Market Share by Regions
      • 3.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Drugs for Herpes Labialis (Oral Herpes) Production
        • 3.4.1 North America Drugs for Herpes Labialis (Oral Herpes) Production Growth Rate (2014-2019)
        • 3.4.2 North America Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Drugs for Herpes Labialis (Oral Herpes) Production
        • 3.5.1 Europe Drugs for Herpes Labialis (Oral Herpes) Production Growth Rate (2014-2019)
        • 3.5.2 Europe Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Drugs for Herpes Labialis (Oral Herpes) Production (2014-2019)
        • 3.6.1 China Drugs for Herpes Labialis (Oral Herpes) Production Growth Rate (2014-2019)
        • 3.6.2 China Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Drugs for Herpes Labialis (Oral Herpes) Production (2014-2019)
        • 3.7.1 Japan Drugs for Herpes Labialis (Oral Herpes) Production Growth Rate (2014-2019)
        • 3.7.2 Japan Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Drugs for Herpes Labialis (Oral Herpes) Consumption by Regions

      • 4.1 Global Drugs for Herpes Labialis (Oral Herpes) Consumption by Regions
      • 4.2 North America Drugs for Herpes Labialis (Oral Herpes) Consumption (2014-2019)
      • 4.3 Europe Drugs for Herpes Labialis (Oral Herpes) Consumption (2014-2019)
      • 4.4 China Drugs for Herpes Labialis (Oral Herpes) Consumption (2014-2019)
      • 4.5 Japan Drugs for Herpes Labialis (Oral Herpes) Consumption (2014-2019)

      5 Global Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price Trend by Type

      • 5.1 Global Drugs for Herpes Labialis (Oral Herpes) Production Market Share by Type (2014-2019)
      • 5.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Type (2014-2019)
      • 5.3 Global Drugs for Herpes Labialis (Oral Herpes) Price by Type (2014-2019)
      • 5.4 Global Drugs for Herpes Labialis (Oral Herpes) Production Growth by Type (2014-2019)

      6 Global Drugs for Herpes Labialis (Oral Herpes) Market Analysis by Applications

      • 6.1 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Market Share by Application (2014-2019)
      • 6.2 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Drugs for Herpes Labialis (Oral Herpes) Business

      • 7.1 GSK
        • 7.1.1 GSK Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.1.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Novartis
        • 7.2.1 Novartis Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.2.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Teva
        • 7.3.1 Teva Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.3.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Mylan
        • 7.4.1 Mylan Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.4.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Cadila
        • 7.5.1 Cadila Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.5.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Apotex
        • 7.6.1 Apotex Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.6.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Daewoong Pharmaceutical
        • 7.7.1 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.7.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Livzon
        • 7.8.1 Livzon Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.8.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 Luoxin
        • 7.9.1 Luoxin Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.9.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 Med shine
        • 7.10.1 Med shine Drugs for Herpes Labialis (Oral Herpes) Production Sites and Area Served
        • 7.10.2 Drugs for Herpes Labialis (Oral Herpes) Product Introduction, Application and Specification
        • 7.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 Bayer (Campho Phenique)
      • 7.12 Blistex
      • 7.13 Kelun Group
      • 7.14 Hikma
      • 7.15 Haiwang
      • 7.16 Carmex
      • 7.17 Cipher

      8 Drugs for Herpes Labialis (Oral Herpes) Manufacturing Cost Analysis

      • 8.1 Drugs for Herpes Labialis (Oral Herpes) Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Drugs for Herpes Labialis (Oral Herpes)
      • 8.4 Drugs for Herpes Labialis (Oral Herpes) Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Drugs for Herpes Labialis (Oral Herpes) Distributors List
      • 9.3 Drugs for Herpes Labialis (Oral Herpes) Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Drugs for Herpes Labialis (Oral Herpes) Market Forecast

      • 11.1 Global Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast
        • 11.1.1 Global Drugs for Herpes Labialis (Oral Herpes) Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Drugs for Herpes Labialis (Oral Herpes) Price and Trend Forecast (2019-2025)
      • 11.2 Global Drugs for Herpes Labialis (Oral Herpes) Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2019-2025)
      • 11.3 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Drugs for Herpes Labialis (Oral Herpes) Consumption Forecast (2019-2025)
        • 11.3.2 Europe Drugs for Herpes Labialis (Oral Herpes) Consumption Forecast (2019-2025)
        • 11.3.3 China Drugs for Herpes Labialis (Oral Herpes) Consumption Forecast (2019-2025)
        • 11.3.4 Japan Drugs for Herpes Labialis (Oral Herpes) Consumption Forecast (2019-2025)
      • 11.4 Global Drugs for Herpes Labialis (Oral Herpes) Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
        Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US.

        The classification of drugs for herpes labialis (oral herpes) includes valacyclovir, aciclovir, famciclovir, docosanol and other. The proportion of aciclovir in 2016 is about 17%, and the proportion of valacyclovir is about 45%.

        Drugs for herpes labialis (oral herpes) are widely used though external use, oral and injection. The most proportion of drugs for herpes labialis (oral herpes) is oral, and the consumption in 2016 is about 1200 M USD.

        North America is the largest consumption place, with a revenue market share nearly 36.5% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 28.4%.

        Market competition is intense. GSK, Novartis, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

        The global Drugs for Herpes Labialis (Oral Herpes) market is valued at 2040 million US$ in 2018 is expected to reach 3030 million US$ by the end of 2025, growing at a CAGR of 5.1% during 2019-2025.
        This report focuses on Drugs for Herpes Labialis (Oral Herpes) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Drugs for Herpes Labialis (Oral Herpes) market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        GSK
        Novartis
        Teva
        Mylan
        Cadila
        Apotex
        Daewoong Pharmaceutical
        Livzon
        Luoxin
        Med shine
        Bayer (Campho Phenique)
        Blistex
        Kelun Group
        Hikma
        Haiwang
        Carmex
        Cipher

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        Aciclovir
        Valacyclovir
        Famciclovir
        Docosanol
        Other

        Segment by Application
        External Use
        Oral
        Injection

        Buy now